Vertex Pharmaceuticals Logo

Email this page: News Release

Phase 3 Study of VX-770 Showed Profound and Sustained Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis

For security reasons, registration is required before you can use this feature.
* Indicates required field